HilleVax, Inc. (NASDAQ:HLVX) Receives Average Rating of “Hold” from Brokerages

Shares of HilleVax, Inc. (NASDAQ:HLVX) have been assigned an average recommendation of “Hold” from the six ratings firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a hold rating. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $3.00.

Separately, HC Wainwright restated a “neutral” rating and set a $2.00 price target on shares of HilleVax in a research note on Monday, March 31st.

Hedge Funds Weigh In On HilleVax

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new position in shares of HilleVax in the fourth quarter valued at approximately $26,000. SG Americas Securities LLC increased its holdings in HilleVax by 61.6% during the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock valued at $38,000 after purchasing an additional 6,916 shares in the last quarter. Ieq Capital LLC raised its position in HilleVax by 71.1% in the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock valued at $47,000 after purchasing an additional 9,344 shares during the last quarter. Barclays PLC boosted its stake in HilleVax by 255.6% in the third quarter. Barclays PLC now owns 42,033 shares of the company’s stock worth $74,000 after purchasing an additional 30,213 shares in the last quarter. Finally, Bank of Montreal Can grew its holdings in shares of HilleVax by 47.1% during the fourth quarter. Bank of Montreal Can now owns 35,763 shares of the company’s stock worth $74,000 after purchasing an additional 11,459 shares during the last quarter. 86.42% of the stock is currently owned by institutional investors and hedge funds.

HilleVax Trading Down 0.5 %

HLVX opened at $1.85 on Friday. The stock’s 50 day simple moving average is $1.69 and its 200-day simple moving average is $1.83. The stock has a market cap of $92.76 million, a PE ratio of -0.60 and a beta of 0.86. HilleVax has a 1 year low of $1.34 and a 1 year high of $16.31.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). Equities analysts forecast that HilleVax will post -2.64 earnings per share for the current fiscal year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.